Annovis Bio, Inc. (ANVS) Stock

Annovis Bio, Inc. (ANVS) is a Healthcare stock trading at $1.81 (as of 2026-08-21), with a market capitalization of $77.12M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Understand Annovis Bio, Inc.: how it makes money

Annovis Bio develops drugs to treat neurodegeneration, led by Buntanetap, an orally administered candidate for Alzheimer’s disease and Parkinson’s disease, and it is currently focused on advancing these clinical-stage programs to create future commercial opportunities.

As a clinical stage drug platform, the company’s ability to reach profitability is fundamentally tied to whether its trials for Buntanetap and its other candidates successfully progress, supported by enrollment and site execution metrics and observed clinical signals.

Business quality (Weak): Strong focus on trial execution for a lead oral compound, but investors should expect high uncertainty because the business is still dependent on clinical outcomes and continued enrollment progress.

Bull case

  • The company is actively running studies for its lead compound, with meaningful ongoing trial activity: It reports 46.0 "Currently Enrolling Patients" and 76.0 "United States Clinical Trial Sites Secured".
  • There are reported cognitive improvement signals in specific study contexts: It reports 3.3 "Alzheimer's Disease ADAS-Cog11 Cognition Improvement" and 3.15 "High-Risk Apolipoprotein E4 Carriers Cognition Improvement".

Bear case

  • Enrollment is exposed to higher-than-ideal screening pressure: It reports a 50.0 "Screen Failure Rate", which can constrain pace and trial scalability.
  • Clinical programs face execution risk even when enrollment is progressing: While the company reports 85.0 "Alzheimer's Disease Phase 3 Trial Enrollment" and 40.0 "Parkinson's Disease Open-Label Extension Enrollment", the outcomes still depend on later trial results and continued patient recruitment.
Valuation — source: SEC EDGAR (first-party)
Price$1.81
Market Cap$77.12M
Price / Sales246.74
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)12.5%
EPS Growth (YoY)-61.9%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($3.19M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMaria L. Maccecchini
Employees8
CountryUS
IPO Date2020-01-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Verrica Pharmaceuticals Inc. (VRCA)
  • Cingulate Inc. (CING)
  • Elicio Therapeutics, Inc. (ELTX)
  • Lunai Bioworks Inc. (LNAI)
  • Telomir Pharmaceuticals, Inc. Common Stock (TELO)
  • Serina Therapeutics, Inc. (SER)
  • iBio, Inc. (IBIO)
  • Pliant Therapeutics, Inc. (PLRX)
ANVS earnings history · ANVS institutional & insider holders · ANVS KPIs & operating metrics · ANVS financials · ANVS investor presentations & press releases · ANVS SEC filings · ANVS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.